Valuation: Quanterix Corporation

Market Cap 183M 160M 148M 137M 258M 17.49B 263M 1.77B 694M 8.59B 686M 671M 29.67B P/E 2026 *
-3.02x
P/E 2027 * -2.92x
Enterprise Value 183M 160M 148M 137M 258M 17.49B 263M 1.77B 694M 8.59B 686M 671M 29.67B EV / Sales 2026 *
1.08x
EV / Sales 2027 * 0.97x
Free-Float
93.7%
Yield 2026 *
-
Yield 2027 * -
1 day-1.16%
1 week-10.49%
Current month-11.11%
1 month+23.87%
3 months+13.27%
6 months-46.37%
Current year-39.62%
1 week 3.77
Extreme 3.77
4.45
1 month 2.82
Extreme 2.825
4.57
Current year 2.4
Extreme 2.395
8.77
1 year 2.4
Extreme 2.395
8.77
3 years 2.4
Extreme 2.395
29.7
5 years 2.4
Extreme 2.395
60.92
10 years 2.4
Extreme 2.395
92.57
Manager TitleAgeSince
Chief Executive Officer 59 2026-01-18
Director of Finance/CFO 50 2026-06-21
Chief Operating Officer - 2026-05-13
Director TitleAgeSince
Director/Board Member 63 2022-06-05
Chairman 64 2025-03-23
Director/Board Member 48 2024-08-18
Date Insider Type Main position Quantity % Market Cap.
07-07Fiscal year

Director

16,146 0.0347%
07-07Fiscal year

Director

16,146 0.0347%
06-30Free

Chairman

5,472 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
-1.42%-10.49%-36.53%-84.42% 183M
+0.46%+2.34%+24.54%+0.58% 196B
+0.88%-5.35%-20.68%+18.07% 144B
+0.49%+3.42%+1.26%-16.15% 141B
-0.02%+0.46%-57.05%-15.13% 66.54B
-0.52%-3.54%+17.28%-1.38% 53.09B
+2.80%+1.95%-22.68%-30.55% 44.12B
-0.89%+1.91%+10.84%+11.52% 37.93B
-1.01%-1.70%+22.45%+38.33% 36.96B
+1.07%+0.76%-12.25%-19.74% 29.43B
Average +0.20%-1.72%-7.28%-9.89% 74.91B
Weighted average by Cap. +0.46%-0.83%-1.33%-0.97%

Financials

2026 *2027 *
Net sales 170M 149M 138M 127M 240M 16.26B 245M 1.65B 645M 7.99B 638M 624M 27.58B 189M 165M 153M 141M 267M 18.05B 272M 1.83B 716M 8.86B 708M 693M 30.61B
Net income -60.86M -53.38M -49.44M -45.49M -86.04M -5.83B -87.72M -589M -231M -2.86B -229M -224M -9.88B -63.85M -56M -51.87M -47.73M -90.27M -6.11B -92.03M -618M -242M -3B -240M -235M -10.36B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
26-07-13 US$3.840 -1.03% 175,231
26-07-10 US$3.880 -2.51% 357,380
26-07-09 US$3.980 +2.84% 461,833
26-07-08 US$3.870 -3.25% 433,142
26-07-07 US$4.000 -6.76% 503,787
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.880USD
Average target price
4.333USD
Spread / Average Target
+11.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock